Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy

被引：4
|
作者：
Matsumoto, Yoshiya [1 ,2 ]
Koh, Yasuhiro [2 ]
机构：
[1] Osaka City Univ, Grad Sch Med, Dept Resp Med, Osaka, Japan
[2] Wakayama Med Univ, Internal Med 3, Wakayama, Japan
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 07期
关键词：
epidermal growth factor receptor; non-small-cell lung cancer; tumor microenvironment; tumor mutational burden; PD-L1; EXPRESSION; MUTATION INCIDENCE; OPEN-LABEL; PHASE IB; DOCETAXEL; NIVOLUMAB; ATEZOLIZUMAB; BLOCKADE; INFILTRATION; CHEMOTHERAPY;
D O I：
10.2217/imt-2019-0213
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：431 / 438
页数：8
相关论文
共 50 条
  • [1] Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer
    Matsumoto, Yoshiya
    Sawa, Kenji
    Fukui, Mitsuru
    Oyanagi, Jun
    Izumi, Motohiro
    Ogawa, Koichi
    Suzumura, Tomohiro
    Watanabe, Tetsuya
    Kaneda, Hiroyasu
    Mitsuoka, Shigeki
    Asai, Kazuhisa
    Kimura, Tatsuo
    Yamamoto, Nobuyuki
    Koh, Yasuhiro
    Kawaguchi, Tomoya
    CANCER SCIENCE, 2019, 110 (10) : 3244 - 3254
  • [2] Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench
    Jin, Rui
    Zhao, Jing
    Xia, Lexin
    Li, Qin
    Li, Wen
    Peng, Ling
    Xia, Yang
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [3] The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer
    Boussageon, Maxime
    Swalduz, Aurelie
    Perol, Maurice
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (10) : 1071 - 1080
  • [4] Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer
    Soo, Ross A.
    Kim, Hye Ryun
    Asuncion, Bernadette Reyna
    Fazreen, Zul
    Omar, Mohamed Feroz Mohd
    Herrera, Maria Cynthia
    Lim, Joey Sze Yun
    Sia, Grace
    Soong, Richie
    Cho, Byoung-Chul
    LUNG CANCER, 2017, 105 : 17 - 22
  • [5] Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
    Wiest, Nathaniel
    Majeed, Umair
    Seegobin, Karan
    Zhao, Yujie
    Lou, Yanyan
    Manochakian, Rami
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] Minimal residual disease in EGFR-mutant non-small-cell lung cancer
    Bain, Nathan T. T.
    Wang, Yang
    Arulananda, Surein
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer
    Han, Rui
    Zhang, Yimin
    Wang, Tianhu
    Xiao, Hualiang
    Luo, Zhilin
    Shen, Cheng
    Li, Jianghua
    Zhao, Chenglong
    Li, Li
    Zhu, Mengxiao
    Du, Haiwei
    Tang, Huan
    Ma, Zheng
    Wang, Yubo
    He, Yong
    CANCER SCIENCE, 2023, 114 (06) : 2569 - 2583
  • [8] Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
    Attili, Ilaria
    Passaro, Antonio
    Corvaja, Carla
    Aliaga, Pamela Trillo
    Del Signore, Ester
    Spitaleri, Gianluca
    de Marinis, Filippo
    CANCER TREATMENT REVIEWS, 2023, 119
  • [9] Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Isomoto, Kohsuke
    Haratani, Koji
    Hayashi, Hidetoshi
    Shimizu, Shigeki
    Tomida, Shuta
    Niwa, Takashi
    Yokoyama, Toshihide
    Fukuda, Yasushi
    Chiba, Yasutaka
    Kato, Ryoji
    Tanizaki, Junko
    Tanaka, Kaoru
    Takeda, Masayuki
    Ogura, Takashi
    Ishida, Tadashi
    Ito, Akihiko
    Nakagawa, Kazuhiko
    CLINICAL CANCER RESEARCH, 2020, 26 (08) : 2037 - 2046
  • [10] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
    Gomes, Jessica Ribeiro
    Cruz, Marcelo Rocha S.
    ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142
12345